nk042
Cell therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 6, 2024 (NCT06415500)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06773091 | Phase 1 | Feb 7, 2025 | Government of China, Peking University |
| NCT06676631 | Phase 1 | Nov 30, 2024 | Shantou University |
| NCT06415500 | Phase 1 | May 6, 2024 | Anhui Medical University, Anhui Province Cancer Hospital |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Anhui Province Cancer Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Shantou University | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1